CompletedNot Applicable

Impact of Diazepam 1% Oral Gel Efficacy in Burning Mouth Syndrome

Italy40 participantsStarted 2020-05-02

Plain-language summary

Burning mouth syndrome (BMS) is a syndrome characterized by burning and persistent oral pain, ranging from mild to intense, in the absence of organic disorders of the oral cavity and with a major impact on the quality of life of the sufferer. Although several etiological theories have been proposed to explain BMS, none has been universally accepted to date, and its origin remains unclear. Currently, several scientific evidences would suggest that underlying BMS would be alterations in certain neuropathic mechanisms. The purpose of the study is to evaluate the efficacy of Diazepam 1% oral gel in the treatment of burning mouth syndrome.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * clinically diagnosed with BMS who reported a history of continuous oral burning pain for more than 4 months with no clinical signs that could justify the syndrome Exclusion Criteria: * • clinically diagnosed with BMS who reported a history of continuous oral burning pain for more than 4 months with clinical signs that could justify the syndrome

What they're measuring

Evolution of burning mouth

Timeframe: 2 Months

Trial details

NCT IDNCT05872789

SponsorUniversity of Catania

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-09-12

View on ClinicalTrials.gov More Burning Mouth Syndrome trials